Ixabepilone: A new chemotherapeutic option for refractory metastatic breast cancer

Biologics: Targets and Therapy

Volumn 2, Issue 3, 2008, Pages 505-515

  Puhalla, Shannon ^a   Brufsky, Adam ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Epothilone; Ixabepilone; Metastatic breast cancer; Taxane refractory

Indexed keywords

EID: 77954659252     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Cancer.gov. 2008a. A phase II combination of trastuzumab and ixabepilone versus trastuzumab and docetaxel in patients with advanced and/or metastatic breast cancer. Accessed 2 January 2008. URL: http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=558843&version=HealthProfessional&protocolsearchid=4256672.
2. Cancer.gov. 2008b. Phase II study of trastuzumab (herceptin) and ixabepilone (BMS-247550) in women with HER2-positive metastatic breast cancer. Accessed 2 January. 2008. URL: http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=355176&version=HealthProfessional&protocolsearchid=4352712.
3. Cancer.gov. 2008c. A trial of 2 schedules of ixabepilone plus bevacizumab and paclitaxel plus bevacizumab for breast cancer. Accessed 2 January 2008. URL: http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=355176&version=HealthProfessional&protocolsearchid=4256672.
4. Abraham J, Agrawal M, Bakke S, et al. 2003. Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J Clin Oncol, 21:1866-73.
5. Aghajanian C, Burris HA 3rd, Jones S, et al. 2007. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. J Clin Oncol, 25:1082-8.
6. Ajani JA, Safran H, Bokemeyer C, et al. 2006. A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane. Invest New Drugs, 24:441-6.
7. Anderson S, Dizon D, Sabbatini J, et al. 2004. Phase I trial of BMS-247550 and gemcitabine in patients with advanced solid tumor malignancies. Proc Am Soc Clin Oncol, 22:abstract 2098.
8. Awada A, Bleiberg H, deValeriola D, et al. 2001. Phase I clinical and pharmacology study of the epothilone analog BMS-247550 given weekly in patinets (pts) with advanced solid tumors. Proc Am Soc Clin Oncol:abstract 427.
9. Baselga J, Gianni L, Llombart A, et al. 2005. Predicting repsonse to ixabepilone: genomics study in patients receiving single agent ixabepilone as neoadjuvant treatment for breast cancer (BC). Breast Cancer Res Treat, 94:s31-s32.
10. Bode CJ, Gupta ML Jr, Reiff EA, et al. 2002. Epothilone and paclitaxel: unexpected differences in promoting the assembly and stabilization of yeast microtubules. Biochemistry, 41:3870-4.
11. Bollag DM, McQueney PA, Zhu J, et al. 1995. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res, 55:2325-33.
12. Bunnell CA, Klimovsky J, Thomas E. 2006. Final efficacy results of a phase I/II trial of ixabepilone in combination with capecitabine in patients with metastatic breast cancer (MBC) previously treated with a taxane and an anthracycline. Proc Am Soc Clin Oncol, 24:abstract 10511.
13. Burris HA, Awada A, Jones S, et al. 2002. Phase I study of the novel epothilone BMS-247550 administered weekly in patietns (pts) with advanced malignancies. Proc Am Soc Clin Oncol:abstract 412.
14. Burstein HJ, Elias AD, Rugo HS, et al. 2008. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol, 26:1810-6.
15. Chen T, Molina A, Moore S, et al. 2004. Epithilone B analog (BMS-247550) at the recommended Phase II dose (RPTD) in patients (pts) with gynecologic (gyn) and breast cancers. J Clin Oncol, 23:abstract 2115.
16. Denduluri N, Lee JJ, Walshe J, et al. 2007b. Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer. Invest New Drugs, 25:63-7.
17. Denduluri N, Low JA, Lee JJ, et al. 2007a. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol, 25:3421-7.
18. Eng C, Kindler HL, Nattam S, et al. 2004. A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer. Ann Oncol, 15:928-32.
19. Fojo AT, Menefee M, Poruchynsky M, et al. 2005. A translational study of ixabepilone (BMS-247550) in renal cell cancer (RCC): assessment of its activity and demonstration of target engagement in tumor cells. J Clin Oncol, 23:abstract 4541.
20. Fumoleau P, Coudert B, Isambert N, et al. 2007. Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues. Ann Oncol, 18(Suppl 5):v9-15.
21. Gadgeel SM, Wozniak A, Boinpally RR, et al. 2005. Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design. Clin Cancer Res, 11:6233-9.
22. Galsky MD, Small EJ, Oh WK, et al. 2005. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol, 23:1439-46.
23. Gerth K, Bedorf N, Hofle G, et al. 1996. Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties. J Antibiot (Tokyo), 49:560-3.
24. Giannakakou P, Gussio R, Nogales E, et al. 2000. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci USA, 97:2904-9.
25. Gradishar WJ, Krasnojon D, Cheporov S, et al. 2006. A randomized phase 2 trial of qw or q3w ABI-007 (ABX) vs. q3w solvent based docetaxel (TXT) as first-line therapy in metastatic breast cancer (MBC). Breast Cancer Res Treat, s21:abstract 46.
26. Gradishar WJ, Tjulandin S, Davidson N, et al. 2005. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol, 23:7794-803.
27. Hao D, Hammond LA, deBono JS, et al. 2002. Continuous weekly administration of the epothilone-B derivative, BMS247,550 (NSC710428): a phase I and pharmacokinetic (PK) study. Proc Am Soc Clin Oncol, 21:abstract 411.
28. He L, Orr GA, Horwitz SB. 2001a. Novel molecules that interact with microtubules and have functional activity similar to taxol. Drug Discov Today, 6:1153-64.
29. He L, Yang CP, Horwitz SB. 2001b. Mutations in beta-tubulin map to domains involved in regulation of microtubule stability in epothiloneresistant cell lines. Mol Cancer Ther, 1:3-10.
30. Hensley ML, Dizon D, Derosa F, et al. 2007. A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors. Invest New Drugs, 25:335-41.
31. Hussain M, Tangen CM, Lara PN Jr, et al. 2005. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol, 23:8724-9.
32. Jordan MA, Wilson L. 2004. Microtubules as a target for anticancer drugs. Nat Rev Cancer, 4:253-65.
33. Lee FY, Borzilleri R, Fairchild CR, et al. 2001. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res, 7:1429-37.
34. Lee FY, Camuso A, Castenada S, et al. 2006. Preclinical studies of ixabepilone (BMS-247550) demonstrate optimal antitumor activity against both chemotherapy-sensitive and -resistant tumor types [abstract]. Proceedings 97th Annual Meeting of the American Association for Cancer Research; 2006 Apr 1-5; Washington DC. Philadelphia (PA). abstract 503.
35. Lee FY, Camuso A, Castenada C, et al. 2006. Preclinical efficacy evaluation of ixbepilone (BMS-247550) in combination with cetuximab or capecitabine in human colon and lung carcinoma xenografts. J Clin Oncol, 24:abstract 12017.
36. Lee JJ, Low JA, Croarkin E, et al. 2006. Changes in neurologic function tests may predict neurotoxicity caused by ixabepilone. J Clin Oncol, 24:2084-91.
37. Llmobart-Cussac A, Baselga G, Manikhas G, et al. 2005. Phase II genomics study in patients receiving Ixabepilone as neoadjuvant treatment for breast cancer (BC): Preliminary efficacy and safety data. J Clin Oncol, 23:abstract 586.
38. Low JA, Wedam SB, Lee JJ, et al. 2005. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol, 23:2726-34.
39. McDaid HM, Mani S, Shen HJ, et al. 2002. Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study. Clin Cancer Res, 8:2035-43.
40. Mani S, McDaid H, Hamilton A, et al. 2004. Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin Cancer Res, 10:1289-98.
41. Mani S, McDaid HM, Grossman A, et al. 2007. Peripheral blood mononuclear and tumor cell pharmacodynamics of the novel epothilone B analogue, ixabepilone. Ann Oncol, 18:190-5.
42. Miller K, Wang M, Gralow J, et al. 2007. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med, 357:2666-76.
43. Miller KD, Sweeney CJ, Sledge GW Jr, et al. 2001. Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol, 19:1195-206.
44. Nogales E, Wolf SG, Khan I, et al. 1995. Structure of tubulin at 6.5 A and location of the Taxol-binding site. Nature, 375:424-7.
45. O'Connor OA, Straus D, Moskowitz C, et al. 2005. Targeting the microtubule apparatus in indolent and mantle cell lymphoma with the novel epothilone analog BMS 247550 induces major and durable remissions in very drug resistant disease. J Clin Oncol, 23: abstract 6569.
46. Ojima I, Chakravarty S, Inoue T, et al. 1999. A common pharmacophore for cytotoxic natural products that stabilize microtubules. Proc Natl Acad Sci USA, 96:4256-61.
47. Okuno S, Maples WJ, Mahoney MR, et al. 2005. Evaluation of epothilone B analog in advanced soft tissue sarcoma: a phase II study of the phase II consortium. J Clin Oncol, 23:3069-73.
48. Pavlick AC, Millward M, Farrell K, et al. 2004. A phase II study of the epothilone B analog (EpoB)-BMS 247550 (NSC710428) in stage IV malignant melanoma. J Clin Oncol, 23:abstract 7542.
49. Perez EA, Lerzo G, Pivot X, et al. 2007. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol, 25:3407-14.
50. Plummer R, Molife R, Verrill M, et al. 2002. Phase I and pharmacokinetic study of BMS-247550 in combination with carboplatin in patients with advanced solid malignancies. Proc Am Soc Clin Oncol, 21: abstract 2125.
51. Roche H, Perez EA, Llombart-Cussac A, et al. 2006. Ixabepilone, an epothilone B analog, is effective in ER, PR, and HER-2 negative (triple negative) patinets (pts): Data from neoadjuvant and metastatic breast cancer (MBC) trials. Ann Oncol, 17:abstract 256P.
52. Roche H, Yelle L, Cognetti F, et al. 2007. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol, 25:3415-20.
53. Rosenberg JE, Weinberg VK, Kelly WK, et al. 2007. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer, 110:556-63.
54. Rugo HS, Stopeck A, Joy AA, et al. 2007. A radomized, double-blind phase II study of the oral tyrosine kinase inhibitor (TKI) axitinib (AG-013736) in combination with docetaxel (DOC) compared to DOC plus placebo (PL) in metastatic breast cancer (MBC). Proc Am Soc Clin Oncol, 25: abstract 1003.
55. Seidman AD, Berry D, Cirrincione C, et al. 2008. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of the Cancer and Leukemia Group B protocol 9840. J Clin Oncol, 26:1642-9.
56. Shimizu T, Yamamoto N, Yamada Y, et al. 2008. Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS- 247550), an epothilone B analog, in Japanese patients with refractory solid tumors. Cancer Chemother Pharmacol, 61:751-8.
57. Singh DA, Kindler HL, Eng C, et al. 2003. Phase II trial of the epothilone B analog BMS-247550 in patients with hepatobiliary cancer. Proc Am Soc Clin Oncol, 22:abstract 1127.
58. Smith SM, Pro B, Van Besien K, et al. 2005. A phase II study of epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin's lymphoma. J Clin Oncol, 23:abstract 6625.
59. Sparano JA, Wang M, Martino S, et al. 2008. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med, 358:1663-71.
60. Spriggs D, Soignet S, Bienvenu B, et al. 2001. Phase I first-in-man study of the epothilone B Analog BMS-247550 in patients with advanced cancer. Proc Am Soc Clin Oncol, 20:abstract 428.
61. Sweeney CJ, Miller KD, Sissons SE, et al. 2001. The antiangiogenic property of docetaxel is synergsitic with a recombinant humanized monoclonal antobody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growht factors. Cancer Res, 61:3369-72.
62. Thambi PM, Edgerly M, Agarwal M, et al. 2003. A phase I clinical trial of BMS-247550 (NSC 71028), an epothilone B derivative, given daily for 3 days on a 21 day cycle in patients with refractory neoplasms. Proc Am Soc Clin Oncol, 22:abstract 540.
63. Thomas E, Tabernero J, Fornier M, et al. 2007. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol, 25:3399-406.
64. Thomas ES, Gomez HL, Li RK, et al. 2007. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol, 25:5210-7.
65. Vansteenkiste J, Lara PN Jr, Le Chevalier T, et al. 2007. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non smallcell lung cancer whose tumors have failed first-line platinum-based chemotherapy. J Clin Oncol, 25:3448-55.
66. Whitehead RP, McCoy S, Rivkin SE, et al. 2006. A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study. Invest New Drugs, 24:515-20.
67. Zhuang SH, Agrawal M, Edgerly M, et al. 2005. A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days. Cancer, 103:1932-8.